- 专利标题： Process for making M1 receptor positive allosteric modulators
-
申请号： US15761754申请日： 2016-09-26
-
公开(公告)号： US10308633B2公开(公告)日： 2019-06-04
- 发明人: Qinghao Chen , Shane W. Krska , Lushi Tan , Peter E. Maligres , Jeremy Scott , Carl Baxter , Gavin William Stewart , Andrew Gibb
- 申请人： Merck Sharp & Dohme Corp.
- 申请人地址： US NJ Rahway unknown Hoddesdon, Hertfordshire
- 专利权人： Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Limited
- 当前专利权人： Merck Sharp & Dohme Corp.,Merck Sharp & Dohme Limited
- 当前专利权人地址： US NJ Rahway unknown Hoddesdon, Hertfordshire
- 代理商 Sylvia A. Ayler; John C. Todaro
- 国际申请： PCT/US2016/053652 WO 20160926
- 国际公布： WO2017/058691 WO 20170406
- 主分类号： C07D239/70
- IPC分类号： C07D239/70 ; C07D401/06 ; C07D401/10 ; A61K31/517 ; A61P25/28
摘要：
This invention provides novel processes for the preparation of compounds such as 3-[(1S,2S)-2-hydroxycyclohexyl]-6-[(6-methylpyridin-3-yl)methyl]benzo[h]-quinazolin-4(3H)-one, salts and derivatives thereof. The compounds synthesized by the processes of the invention are useful for treating Alzheimer's disease and other diseases (e.g., cognitive impairment, schizophrenia, pain disorders, and sleep disorders) mediated by the muscarinic M1 receptor.